$JNJ · Johnson & Johnson
Latest call · 2026-10-12
The call
Head-to-head · Claude vs the Street vs reality
| Claude | Street | Actual | |
|---|---|---|---|
| EPS | $2.58 | $2.54 | ⏳ pending |
| Revenue | $25.50B | $25.38B | — |
| Direction (1d) | 🟢 UP |
🟢 UP
11B · 7H · 1S
|
— |
| 1d move | +0.8% | — | — |
| 3d move | +1.5% | — | — |
Thesis
JNJ hits the steepest Stelara biosimilar comparison this quarter — but the LOE is the most-modeled drug cliff in large-cap pharma. Oncology (Rybrevant/Carvykti) and MedTech margin flow-through (Shockwave/Abiomed) are the hidden-upside levers. We see $2.58 EPS vs Street $2.54; slim beat with raise-of-guide optionality.
What would flip it
Flat FY26 guide (no mid-point raise) breaks the compounder tape.
The market's narrative
The Stelara biosimilar cliff is 760bps of Innovative Medicine drag — Q3 will be the steepest comparison. FY26 raised guide ($100.8-$101.4B rev / $11.60-$11.75 adj EPS at Q2) sets a confirming bar. Oncology (Darzalex/Carvykti) + MedTech + Icotyde data carry the growth story through the Stelara trough.
Where the Street may be wrong
- MedTech margin inflection — the Shockwave + Abiomed integrations are now showing synergy flow-through at the segment-margin line; Street still models cost-side drag
- Oncology launch cadence — Rybrevant (NSCLC) US-launch quarter capture rate running ahead of plan per Q2 commentary
- Icotyde readout tailwind — the Oct ESMO abstracts show strong two-year PFS data; growth-story support ahead of FY27 guide
Peer read: PFE/MRK haven't printed. ABT/BSX MedTech reads positive. UNH print same day creates sector-sentiment co-move risk.
Reasoning
- Classic defensive-compounder setup — composite rec 1.89 (Strong Buy), SMA200 +8.13% (strongest of the wall), low vol positioning. Stelara LOE is the most-forecasted drug cliff in large-cap pharma; the base-effect bear case is fully priced.
- Finviz tech: RSI 49.08 neutral, SMA20 -0.58%, SMA50 -0.93% — tight consolidation 6% below 52w high ($281.07). Not stretched, not washed out.
- Q2 raise ($0.10 to midpoint) sets a confirming/raising bar for Q3; underperforming Q2 narrative-tone would be the trigger for a FLAT-to-DOWN print.
- My estimate $2.58 EPS / $25.50B rev — slim beat with raise-of-guide optionality driven by Oncology + MedTech outperformance.
- Call UP +0.8% 1d, +1.5% 3d LOW conf — defensive-compounder magnitude is small-single-digit; co-move with UNH same morning creates execution noise.
Risks to the call
- FY26 guide held flat (no mid-point raise) — buy-side has been penciling in a 'raise-into-cliff-closure' narrative; neutral guide is the surprise
- MedTech sequential growth decelerates — Abbott's Oct 15 print would then compound the healthcare-sector selloff